Table 8.
Benefit cohort | Population size (millions) | Average age at MDA treatment | Average years of health and economic benefita | Person-years (millions)b |
---|---|---|---|---|
1. Protected from acquiring infection | 21 | 20 | 45.6 | 938 |
2. Subclinical morbidity prevented from progressing | 12.5 | 20 | 45.6 | 551 |
3. Alleviated clinical disease | 12.8 | 30 | 35.6 | 450c |
Total | 46 | - | - | 1,939 |
aBased on a global weighted average life expectancy of 64.6 years (weighted based on the benefit cohort population size in each endemic country)
bThe sum of the number of years lived by each individual in the benefit cohort population. (Equal to the benefit cohort population multiplied by the average years of health and economic benefit (after adjusting for mortality))
cIncludes both those with alleviated chronic disease and these with reduced frequency of ADL episodes (Fig. 3)